Follow on Extension of XT-150-1-0201

Osteoarthritis, Knee Clinical Trial

Official title:

XT-150-1-0201 Extension: Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03769662
• Other study ID #: XT-150-1-0203
• Status: Completed
• Phase: Phase 1
• Start date: March 20, 2019
• Est. completion date: December 30, 2019

Study information

• Verified date: December 2019
• Source: Xalud Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

XT-150 safety and efficacy in severe osteoarthritic pain.

Description:

XT-150-1-0201 Extension: Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain.

Participants in this study will have been enrolled in the 0201 study and qualify for an intra-articular injection of XT-150 into the osteoarthritic knee.

The study will assess XT-150 safety, tolerability, and efficacy in participants who received placebo in the 0201 study, or have a second qualifying knee, or a second injection into the same knee that was treated in 0201.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: December 30, 2019
• Est. primary completion date: October 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Qualified and participated in clinical study XT-150-1-0201.

1. Participant was assigned to placebo, or

2. Participant elects to have XT-150 administered to the XT-150-untreated knee that qualified under XT-150-1-0201 criteria, or

3. Participant had inadequate pain relief and elects to receive a second injection to the same knee treated on clinical study XT-150-1-0201

2. Sufficiently severe OA of knee to require/have recommended knee replacement surgery or be unsuitable for knee replacement surgery based on co-morbidities or orthopedic considerations; be free of local or intra-articular infection.

3. Symptomatic disease because of osteoarthritis, defined as a Verbal Numerical Rating Scale (VNRS) scores of a worst pain of at least 7 at any time during the preceding week (based on scale of 0 to 10, with 10 representing "pain as bad as you can imagine").

4. Stable analgesic regimen during the 4 weeks prior to enrollment.

5. Inadequate pain relief (minimum = 5 mean on Brief Pain Inventory-Severity Scale) lasting more than 3 months.

6. In the judgment of the Investigator, acceptable general medical condition

7. Life expectancy >6 months

8. Male participants who are heterosexually active and not surgically sterile must agree to use effective contraception, including abstinence, for the duration of the study and for 3 months after the study is completed.

9. Have suitable knee joint anatomy for intra-articular injection

10. Willing and able to return for the follow-up (FU) visits

11. Able to reliably provide pain assessment

12. Able to read and understand study instructions, and willing and able to comply with all study procedures

Exclusion Criteria:

1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study drug, including double-stranded DNA, mannose, and sucrose

2. Scheduled knee replacement within 4 months; participant agrees not to schedule a knee replacement appointment within 4 months of study treatment

3. History of rheumatoid arthritis of the knee or gout.

4. High peri-operative risks which in the judgment of the investigator preclude a safe knee injection procedure (e.g., poorly controlled diabetes, cardiac inadequacy such as NYHA class > II, G4 glomerular filtration rate [eGFR < 30 mL/min by Cockcroft-Gault])

5. Current treatment with immunosuppressive (systemic corticosteroid therapy [equivalent to >10mg/day prednisone] or other strong immunosuppressant)

6. History of immunosuppressive therapy; high-potency systemic steroids in the last 3 months.

7. Currently receiving systemic chemotherapy or radiation therapy for malignancy

8. Clinically significant hepatic disease as indicated by clinical laboratory results =3 times the upper limit of normal for any liver function test (e.g., aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase)

9. Severe anemia (Grade 3; hemoglobin <8.0 g/dL, <4.9 mmol/L, <80 g/L; transfusion indicated), uncontrolled coagulopathy (Grade 1, prolonged activated partial prothrombin time (aPTT) > upper limit of normal (ULN) to 1.5xULN), or bleeding diathesis, Grade 1 white cell counts (lymphocytes <LLN - 800/mm3; <LLN - 0.8 x 109 /L, neutrophils <LLN - 1500/mm3; <LLN - 1.5 x 109 /L)

10. Significant neuropsychiatric conditions; dementia, major depression, or altered mental state that in the opinion of the Investigator will interfere with study participation

11. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical treatments)

12. Current treatment with anticoagulants, other than low-dose aspirin.

13. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1 year before the screening visit

14. Women of child-bearing potential

15. Use of any investigational drug, other than XT-150, or device within 1 month before enrollment or current participation in a trial that included intervention with a drug or device; or currently participating in an investigational drug or device study.

16. Any condition that, in the opinion of the Principal Investigator, could compromise the safety of the participant, the participant's ability to communicate with the study staff, or the quality of the data

Related Conditions & MeSH terms

• Osteoarthritis, Knee

Intervention

Biological:
• XT-150
IL-10 transgene DNA plasmid injected into the knee synovial capsule

Locations

Country	Name	City	State
Australia	CMAX Clinical Research Pty Ltd in collaboration with University of Adelaide	Adelaide	South Australia

Sponsors (1)

Lead Sponsor	Collaborator
Xalud Therapeutics, Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events	Clinical Pathology, adverse events	6 months
Secondary	Verbal Numeric Rating Score	Pain scale from 1 to 10, 10 being worst possible	6 months
Secondary	KOOS	Osteoarthritis pain, symptoms, impact on daily living, and quality of life. Subset scores are calculated such that 100% is normal function	6 months
Secondary	Brief Pain Inventory	Pain and interference on daily living functions. Scales ranges from 0 to 10, with 10 being the worst	6 months
Secondary	Clinical Global Improvement	0 - 7 Scale, 4 and below indicate no change or improvement. Over 4 indicates degrees of worsening	6 months